Pfizer Moves Toward a Depo-Provera Settlement. Here Is What It Means for Nevada Women

Thousands of women nationwide, including at least one Nevada claimant, say the birth control shot Depo-Provera caused brain tumors after years of use. A settlement framework is now taking shape, but the deadline to act has not gone away.

What the Lawsuits Allege

The litigation centers on Depo-Provera, a widely prescribed birth control injection, and claims that years of repeated use is linked to an increased risk of meningioma, a usually benign but sometimes disabling tumor that grows on the membranes surrounding the brain and spinal cord. Plaintiffs say the manufacturer knew or should have known about this risk long before it was reflected on the drug's label.

In December 2025, the FDA approved an updated warning label addressing meningioma risk, a shift from the agency's earlier rejection of a similar proposed warning. That label change has become a central piece of evidence for plaintiffs arguing the risk was recognized well before patients were adequately warned.

Where the Litigation Stands Now

As of July 2026, more than 5,800 claims are consolidated in the federal multidistrict litigation, a sharp jump from a few hundred cases when the docket was first formed. In June 2026, the manufacturer agreed to resolve a substantial share of the pending federal claims, and the court has since paused certain trial deadlines while the parties finalize settlement terms.

That agreement does not automatically extend to lawsuits filed in state courts, and case volume nationwide has continued climbing by hundreds of new filings a month for much of the year. A first bellwether trial is still scheduled for later in 2026, a proceeding that will help set the framework for how remaining cases are valued if a broader settlement is not finalized first.

Why Nevada Is Now Part of the Story

A federal lawsuit filed on behalf of a Nevada woman recently expanded the litigation to a state that had not previously had its own filed case in this docket. The claim describes more than a decade of use of the injection followed by a meningioma diagnosis that required surgery, a pattern consistent with many of the other cases already consolidated in the federal litigation.

That filing matters for other Nevada residents because it confirms the litigation is not confined to a handful of states. Anyone in Nevada who used Depo-Provera long term and was later diagnosed with a meningioma or similar tumor may have a claim worth evaluating, regardless of where the drug was originally prescribed or filled.

What Nevada Women Should Do Now

A pending settlement framework is good news for people who already have a case on file, but it does not help someone who never filed a claim in the first place. Nevada generally limits how long an injured person has to bring a product liability claim, and that clock typically starts running from diagnosis rather than from when the drug was first used.

Litigators for Justice offers a free, confidential review for anyone who used Depo-Provera for an extended period and was later diagnosed with a brain or spine tumor. Medical records connecting the two are the most important piece of evidence, and gathering them sooner rather than later helps preserve a claim before any filing deadline passes.

• Gather pharmacy or medical records showing the length of time Depo-Provera was used
• Obtain the pathology report or surgical records from the tumor diagnosis and treatment
• Do not assume a national settlement automatically covers a claim that was never filed
• Ask an attorney about Nevada's filing deadline before assuming it is too late

Signs a Depo-Provera Claim May Be Worth Evaluating

Not every meningioma diagnosis is connected to Depo-Provera use, but these factors commonly appear in claims being evaluated for the litigation.

1. Long-term use: Use of the injection for a year or more, often spanning several years, is typical in claims under review.
2. A confirmed meningioma diagnosis: Imaging and pathology confirming a meningioma or similar brain or spine tumor supports a claim.
3. Surgery or radiation treatment: Many claims involve invasive treatment to remove or manage the tumor.
4. Neurological symptoms: Headaches, vision changes, hearing problems, or memory issues often preceded diagnosis in reported cases.
5. A gap between use and diagnosis: Tumors linked to the drug are frequently diagnosed years after use began.
6. Documentation of the prescription history: Pharmacy or insurance records showing repeated refills help establish the duration of use.

Frequently asked questions

Does the Pfizer settlement mean my claim is automatically resolved?

Not necessarily. The agreement applies to eligible claims already filed in the federal MDL and does not automatically cover state court cases or claims that have not been filed yet.

How long did I need to use Depo-Provera to have a potential claim?

Most claims under review involve use of a year or longer, though an attorney can evaluate shorter periods on a case by case basis.

Is there still time to file a Depo-Provera claim in Nevada?

Filing deadlines generally run from diagnosis rather than first use, but they do not stay open indefinitely. It is worth having a claim reviewed promptly.

What if I already settled a related claim years ago?

Prior settlements involving different claims or different drugs do not necessarily bar a new claim tied specifically to a meningioma diagnosis, but the details matter and should be reviewed individually.